Canertinib (CI-1033) is primarily used in cancer research and treatment, particularly for targeting cancers driven by the overexpression or mutation of the epidermal growth factor receptor (EGFR). It functions as a potent and irreversible inhibitor of EGFR tyrosine kinase, which plays a critical role in cell proliferation and survival. This makes it a valuable tool in studying and treating cancers such as non-small cell lung cancer, breast cancer, and glioblastoma, where EGFR signaling is often dysregulated. Additionally, it is utilized in preclinical studies to understand resistance mechanisms to EGFR inhibitors and to explore combination therapies with other anticancer agents. Its ability to block multiple ErbB family receptors also broadens its potential application in targeting various tumor types.